The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Ontology highlight
ABSTRACT: Ruxolitinib is the first approved JAK1 and JAK2 inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical cellular signaling pathways involved in the inflammatory response. This review presents an overview of SARS-CoV-2 and the COVID-19 pandemic, and then focuses on the potential efficacy of ruxolitinib in this infection. The potential targets of ruxolitinib were determined by using genetic alterations that have been reported in COVID-19 patients. The potential effectiveness of ruxolitinib is suggested by evaluating the interactions of these potential targets with ruxolitinib or JAK/STAT pathway.
SUBMITTER: Goker Bagca B
PROVIDER: S-EPMC7305753 | BioStudies | 2020-01-01
REPOSITORIES: biostudies
ACCESS DATA